A Phase 1 interventional study of Dabigatran etexilate and Diclofenac in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the relative bioavailability of dabigatran with and without concomitant administration of diclofenac and the relative bioavailability of diclofenac with and without concomitant administration of dabigatran etexilate
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dabigatran etexilate
Drug: Diclofenac
Drug: Dabigatran etexilate · Drug: Diclofenac
AUCτ,ss on Day 4 (area under the concentration-time curve of dabigatran in plasma at steady state over one dosing interval)
Time frame: from pre-dose up to 72 hours post-dose
Cmax,ss (maximum concentration of dabigatran in plasma at steady state)
Time frame: from pre-dose up to 72 hours post-dose
Cmax (maximal concentration of diclofenac in plasma)
Time frame: from pre-dose up to 72 hours post-dose
AUC0-infinity (area under the concentration-time curve of diclofenac in plasma extrapolated to infinity)
Time frame: from pre-dose up to 72 hours post-dose
aPTT (activated partial thromboplastin time) and ECT (Ecarin clotting time) with and without diclofenac
Time frame: from pre-dose up to 72 hours post-dose
AUERτ,ss (area under the effect ratio-time curve of dabigatran in plasma at steady state over a uniform dosing interval τ)
Time frame: from pre-dose up to 72 hours post-dose
ERmax,ss (maximal effect ratio of dabigatran in plasma at steady state)
Time frame: from pre-dose up to 72 hours post-dose
AUC0-tz,ss (area under the concentration-time curve of dabigatran in plasma from the time point 0 after the last dose at steady state to the last quantifiable dabigatran plasma concentration within the uniform dosing interval τ)
Time frame: from pre-dose up to 72 hours post-dose
tz,ss (time of last measurable concentration of dabigatran in plasma within the dosing interval τ at steady state)
Time frame: from pre-dose up to 72 hours post-dose
tmax,ss (time from last dosing to the maximum concentration of dabigatran in plasma at steady state on Day 4)
Time frame: from pre-dose up to 72 hours post-dose
CL/Fss (apparent clearance of dabigatran in the plasma at steady state after extravascular multiple dose administration)
Time frame: from pre-dose up to 72 hours post-dose
CLR,ss (renal clearance of dabigatran at steady state determined over the dosing interval τ)
Time frame: from pre-dose up to 72 hours post-dose
C min,ss (minimum measured concentration of dabigatran in plasma at steady state over a uniform dosing interval τ)
Time frame: from pre-dose up to 72 hours post-dose
tmin,ss (time from last dosing to the minimum concentration of dabigatran in plasma at steady state over a uniform dosing interval τ)
Time frame: from pre-dose up to 72 hours post-dose
Cpre,ss (pre-dose concentration of dabigatran in plasma at steady state immediately before administration of the next dose)
Time frame: from pre-dose up to 72 hours post-dose
MRTp.o.,ss (mean residence time of dabigatran in the body at steady state after oral administration)
Time frame: from pre-dose up to 72 hours post-dose
Vz/Fss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)
Time frame: from pre-dose up to 72 hours post-dose
Aeτ,ss (amount of dabigatran that is eliminated in urine at steady state over a uniform dosing interval τ)
Time frame: 0 to 12 h and 12 to 24 h after administration on day 4
feτ,ss (fraction of parent drug eliminated in urine at steady state over a uniform dosing interval τ)
Time frame: 0 to 12 h and 12 to 24 h after administration on day 4
AUC0-tz (area under the concentration-time curve of diclofenac and 4´- hydroxydiclofenac in plasma over the time interval 0 to the last quantifiable analyte plasma concentration after single dose administration)
Time frame: from pre-dose up to 72 hours post-dose
tz (time of last measurable concentration of diclofenac and 4´- hydroxydiclofenac in plasma following a single dose)
Time frame: from pre-dose up to 72 hours post-dose
%AUCtz-infinity (percentage of the AUC0-infinity that is obtained by extrapolation) for diclofenac and 4´- hydroxydiclofenac
Time frame: from pre-dose up to 72 hours post-dose
tmax (time from dosing to the maximum concentration of diclofenac and 4´- hydroxydiclofenac in plasma following a single dose)
Time frame: from pre-dose up to 72 hours post-dose
λz (terminal rate constant in plasma after a single dose) for diclofenac and 4´- hydroxydiclofenac
Time frame: from pre-dose up to 72 hours post-dose
t1/2 (terminal half-life of diclofenac and 4´- hydroxydiclofenac in plasma after a single dose)
Time frame: from pre-dose up to 72 hours post-dose
MRTp.o. (mean residence time of diclofenac and 4´- hydroxydiclofenac in the body after single dose oral administration)
Time frame: from pre-dose up to 72 hours post-dose
CL/F (apparent clearance of diclofenac and 4´- hydroxydiclofenac in the plasma after extravascular single dose administration)
Time frame: from pre-dose up to 72 hours post-dose
Vz/F (apparent volume of distribution during the terminal phase λz following extravascular dose) for diclofenac and 4´- hydroxydiclofenac
Time frame: from pre-dose up to 72 hours post-dose
No study locations are listed for this record.
The record gives a start of May 2006 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabigatran · Diclofenac